Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Defense Health Agency Aurora, on behalf of the Department of War, has issued solicitation HT9402-26-Q-9301 to support the establishment of an integrated pharmacy benefits program for the Military Health System. In accordance with 10 U.S.C. § 1074g, the Pharmacy and Therapeutics (P&T) Committee evaluates the clinical and cost effectiveness of pharmaceutical agents to determine their placement on the Uniform Formulary. This solicitation seeks quotes for specific drug classes scheduled for review during the August 2026 P&T Committee meeting, including ADHD Agents – Stimulants and Oncological Agents – BRAF-MEK Inhibitors. The government may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the resulting formulary decisions.

This requirement is classified under NAICS 325412 Pharmaceutical Preparation Manufacturing and PSC 6505 Drugs and Biologicals. No set-aside has been designated for this procurement. The primary place of performance is San Antonio, Texas. Responses are due by June 29, 2026, following a pre-quotation teleconference scheduled for May 13, 2026. The solicitation includes six attachments, such as the RFQ document, price lists for the identified drug classes, and an FAQ regarding National Drug Code (NDC) price lists.

The review specifically covers brand-name agents such as Azstarys, Cotempla XR-ODT, Dyanavel XR, Jornay PM, Mydayis, Quillichew ER, Quillivant XR, and Xelstrym in the stimulants category. The oncological review includes Braftovi, Cotellic, Mekinist, Mektovi, Tafinlar, and Zelboraf. The P&T Committee uses these quotes to classify agents as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary for cost-sharing and procurement purposes. Tracy Banks serves as the point of contact for this notice.